US-based medical device firm Lombard Medical has entered into a three-year group purchasing agreement with health care services firm Novation to supply its Aorfix endovascular stent graft.
Under the deal, Lombard Medical will provide Aorfix to around 100,000 healthcare institutions that are served by Novation in the US.
Aorfix is an endovascular stent graft system that has been developed to treat infra-renal aortic and aorto-iliac aneurysms or abdominal aortic aneurysms (AAAs).
Lombard Medical CEO Simon Hubbert said: "Through this new agreement with Novation, we are able to offer more physicians in the US the option to treat AAA patients with Aorfix.
"The designation of Innovative Technology reflects the excellent clinical outcomes demonstrated by Aorfix in the Pythagoras study and further supports our belief that Aorfix provides a safe, effective, on-label solution for a greater population of AAA patients than any other AAA stent graft."
According to Lombard, Aorfix is the first and only endovascular stent graft with global approvals to treat patients with aortic neck angulations up to 90 degrees.
It features an exclusive helical and circular design, which allows it to conform to the natural contours of the human anatomy, including aortic necks with high angulations and iliac arteries with extreme bends.
Aorfix obtained FDA approval in 2013 and it is now commercially available in the US, UK, Germany, Spain, Italy, Austria, Switzerland, the Czech Republic, Russia and others.